Stifel raised the firm’s price target on Tandem Diabetes (TNDM) to $16 from $15 and keeps a Hold rating on the shares. Going into the Q3 print, the implied Q4 step-up appeared to hit Tandem’s FY25 revenue guidance, though better-than-expected Q3 results allow the Q4 bar to come down as Tandem’s overall 2025 revenue guide remained unchanged, the analyst tells investors in a research note. The firm added that its concerns remain around pump share until the company’s pipeline takes hold, and the limited amount of visibility into price realization in the pharmacy channel.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Tandem Diabetes price target raised to $16 from $14 at Goldman Sachs
- Tandem Diabetes price target raised to $18 from $16 at Mizuho
- Tandem Diabetes Care: Strong Buy Rating Backed by Strategic Growth Initiatives and Attractive Valuation
- Tandem Diabetes price target raised to $55 from $51 at Barclays
- Tandem Diabetes price target raised to $18 from $16 at Baird